Literature DB >> 28003598

iTRAQ-based Quantitative Proteomics Study in Patients with Refractory Mycoplasma pneumoniae Pneumonia.

Jia-Lu Yu1, Qi-Fang Song2, Zhi-Wei Xie1, Wen-Hui Jiang1, Jia-Hui Chen1, Hui-Feng Fan1, Ya-Ping Xie1, Gen Lu1.   

Abstract

Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia in children and young adults. Although MP pneumonia is usually benign and self-limited, in some cases it can develop into life-threating refractory MP pneumonia (RMPP). However, the pathogenesis of RMPP is poorly understood. The identification and characterization of proteins related to RMPP could provide a proof of principle to facilitate appropriate diagnostic and therapeutic strategies for treating paients with MP. In this study, we used a quantitative proteomic technique (iTRAQ) to analyze MP-related proteins in serum samples from 5 patients with RMPP, 5 patients with non-refractory MP pneumonia (NRMPP), and 5 healthy children. Functional classification, sub-cellular localization, and protein interaction network analysis were carried out based on protein annotation through evolutionary relationship (PANTHER) and Cytoscape analysis. A total of 260 differentially expressed proteins were identified in the RMPP and NRMPP groups. Compared to the control group, the NRMPP and RMPP groups showed 134 (70 up-regulated and 64 down-regulated) and 126 (63 up-regulated and 63 down-regulated) differentially expressed proteins, respectively. The complex functional classification and protein interaction network of the identified proteins reflected the complex pathogenesis of RMPP. Our study provides the first comprehensive proteome map of RMPP-related proteins from MP pneumonia. These profiles may be useful as part of a diagnostic panel, and the identified proteins provide new insights into the pathological mechanisms underlying RMPP.

Entities:  

Keywords:  Differentially expressed proteins; Quantitative proteomics; Refractory Mycoplasma pneumoniae pneumonia

Mesh:

Substances:

Year:  2016        PMID: 28003598     DOI: 10.7883/yoken.JJID.2016.355

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  5 in total

Review 1.  Emergent Pneumonia in Children.

Authors:  Cecilia Perret; Nicole Le Corre; Jose A Castro-Rodriguez
Journal:  Front Pediatr       Date:  2021-06-17       Impact factor: 3.418

2.  Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients.

Authors:  Jin-Rong Liu; Jie Lu; Fang Dong; Hui-Min Li; Hui Liu; Xiao-Lei Tang; Yong-Li Guo; Shun-Ying Zhao
Journal:  Front Pediatr       Date:  2018-10-26       Impact factor: 3.418

3.  Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy.

Authors:  Zhenli Zhu; Tongqiang Zhang; Wei Guo; Yaoyao Ling; Jiao Tian; Yongsheng Xu
Journal:  BMC Infect Dis       Date:  2021-01-28       Impact factor: 3.090

4.  Chinese Herbal Medicine for the Treatment of Children and Adolescents With Refractory Mycoplasma Pneumoniae Pneumonia: A Systematic Review and a Meta-Analysis.

Authors:  Xiaoying Ling; Xun Sun; Huimin Kong; Shanshan Peng; Zheng Yu; Jiali Wen; Bin Yuan
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

5.  Pathogenic Analysis of the Bronchoalveolar Lavage Fluid Samples With Pediatric Refractory Mycoplasma pneumoniae Pneumonia.

Authors:  Fei Zhao; Jinrong Liu; Di Xiao; Liyong Liu; Jie Gong; Juan Xu; Huimin Li; Shunying Zhao; Jianzhong Zhang
Journal:  Front Cell Infect Microbiol       Date:  2020-10-28       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.